Quoin Pharmaceuticals Ltd ADR (QNRX)

$8.06 -0.03 (-0.37%)
Market Cap 6.76M
Revenue (ttm) 0.00
Net Income (ttm) -8.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 10,200
Avg Vol 30,360
Day's Range N/A - N/A
Shares Out 839,000.00
Stochastic %K 16%
Beta 1.60
Analysts Strong Sell
Price Target $26.33

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 980 4182
Address:
42127 Pleasant Forest Court, Ashburn, United States
tackotim
tackotim Mar. 14 at 8:24 PM
$QNRX no one seems to have noticed the positive news trickling in on this
0 · Reply
DetectingRunners
DetectingRunners Mar. 12 at 2:10 AM
$QNRX had news this morning, anyone catch it? Whats the float here btw?
0 · Reply
focafoca99
focafoca99 Mar. 11 at 10:33 PM
$QNRX good news after hours! https://www.rapidticker.com/news/qnrx-sec-filing-1d7cb7
0 · Reply
Telll
Telll Mar. 11 at 12:57 PM
$QNRX fast track
0 · Reply
DARKP00L
DARKP00L Mar. 11 at 12:49 PM
$QNRX 08:41 on Mar. 11 2026 Quoin Pharmaceuticals Receives FDA's Fast Track Designation To QRX003 Lotion To Treat Netherton Syndrome #tradeideas
0 · Reply
TA_Kongen
TA_Kongen Mar. 11 at 12:39 PM
$QNRX Unfortunately the business prospect of treating this syndrome is lacking. Good for the patients though.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 11 at 12:35 PM
$QNRX (+4.8% pre) Quoin Pharmaceuticals receives FDA fast track designation for QRX003 https://ooc.bz/l/96255
0 · Reply
StockNews_Live
StockNews_Live Mar. 11 at 12:31 PM
$QNRX 🎯 STOCK NEWS ALERT 💵 Price: $8.59 (+1.87%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare and… 📎 https://stocknews.live/news/QNRX/quoin-pharmaceuticals-announces-fda-78429.html
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 11 at 12:31 PM
$QNRX - Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 11 at 12:31 PM
$QNRX QNRX Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
0 · Reply
Latest News on QNRX
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Mar 11, 2026, 8:30 AM EDT - 4 days ago

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Jan 27, 2026, 8:30 AM EST - 6 weeks ago

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Jan 20, 2026, 8:30 AM EST - 7 weeks ago

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 4 months ago

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 30, 2025, 8:30 AM EDT - 4 months ago

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Crude Oil Falls Over 4%; Quoin Pharmaceuticals Shares Spike Higher

Oct 10, 2025, 12:56 PM EDT - 5 months ago

Crude Oil Falls Over 4%; Quoin Pharmaceuticals Shares Spike Higher

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Oct 10, 2025, 9:24 AM EDT - 5 months ago

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Sep 9, 2025, 8:30 AM EDT - 6 months ago

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Aug 12, 2025, 8:30 AM EDT - 7 months ago

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Quoin Pharmaceuticals Provides Product Portfolio Update

Jul 29, 2025, 8:30 AM EDT - 8 months ago

Quoin Pharmaceuticals Provides Product Portfolio Update

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 20, 2025, 7:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

May 14, 2025, 7:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 10, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 31, 2025, 4:18 AM EDT - 1 year ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Mar 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 27, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 25, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Feb 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 23, 2025, 5:30 AM EST - 1 year ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Jan 6, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 20, 2024, 9:20 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 19, 2024, 8:00 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Dec 18, 2024, 8:18 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 6, 2024, 5:00 AM EDT - 1 year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 25, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 9, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:10 PM EDT - 2 years ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 12:57 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Mar 7, 2024, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Feb 14, 2024, 9:00 AM EST - 2 years ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Dec 13, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 10:51 AM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 8, 2023, 5:46 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Nov 3, 2023, 8:41 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 9:32 AM EDT - 2 years ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 1:24 AM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Aug 2, 2023, 4:45 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

tackotim
tackotim Mar. 14 at 8:24 PM
$QNRX no one seems to have noticed the positive news trickling in on this
0 · Reply
DetectingRunners
DetectingRunners Mar. 12 at 2:10 AM
$QNRX had news this morning, anyone catch it? Whats the float here btw?
0 · Reply
focafoca99
focafoca99 Mar. 11 at 10:33 PM
$QNRX good news after hours! https://www.rapidticker.com/news/qnrx-sec-filing-1d7cb7
0 · Reply
Telll
Telll Mar. 11 at 12:57 PM
$QNRX fast track
0 · Reply
DARKP00L
DARKP00L Mar. 11 at 12:49 PM
$QNRX 08:41 on Mar. 11 2026 Quoin Pharmaceuticals Receives FDA's Fast Track Designation To QRX003 Lotion To Treat Netherton Syndrome #tradeideas
0 · Reply
TA_Kongen
TA_Kongen Mar. 11 at 12:39 PM
$QNRX Unfortunately the business prospect of treating this syndrome is lacking. Good for the patients though.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 11 at 12:35 PM
$QNRX (+4.8% pre) Quoin Pharmaceuticals receives FDA fast track designation for QRX003 https://ooc.bz/l/96255
0 · Reply
StockNews_Live
StockNews_Live Mar. 11 at 12:31 PM
$QNRX 🎯 STOCK NEWS ALERT 💵 Price: $8.59 (+1.87%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare and… 📎 https://stocknews.live/news/QNRX/quoin-pharmaceuticals-announces-fda-78429.html
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 11 at 12:31 PM
$QNRX - Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 11 at 12:31 PM
$QNRX QNRX Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
0 · Reply
Shodan84
Shodan84 Mar. 10 at 7:41 PM
$QNRX
0 · Reply
RunningRobert1
RunningRobert1 Mar. 10 at 4:40 PM
$QNRX Sold out of my position for a -6% loss, did not like the market and we will see if I buy in at a cheaper position
0 · Reply
stockmoe12
stockmoe12 Mar. 3 at 2:21 AM
$QNRX waiting for approval $200M Voucher … should follow same path like $PVLA very soon…
0 · Reply
StayPresent
StayPresent Mar. 2 at 1:08 PM
$QNRX dilute, RS, dilute RS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 11:44 AM
$QNRX RSI: 63.47, MACD: -0.4533 Vol: 0.70, MA20: 8.16, MA50: 10.54 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
revuelto
revuelto Feb. 26 at 10:37 PM
$QNRX no dilution before this crosses $100 a share✌️
0 · Reply
WhoDoneIt69
WhoDoneIt69 Feb. 26 at 9:43 PM
$QNRX will dilute you into oblivion!
0 · Reply
ZacksSCR
ZacksSCR Feb. 25 at 6:26 PM
$QNRX: Several Recent Milestones - Cash Runway Extended into ‘27, Orphan Drug Designation Received, Positive Interim Data https://buff.ly/fNnRAIk
0 · Reply
bobbydoles
bobbydoles Feb. 25 at 3:20 PM
$FGL launch mode $LRMR $LUNR $QNRX
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 2:42 PM
$QNRX Current Stock Price: $8.74
0 · Reply
6GodEnergy
6GodEnergy Feb. 24 at 7:07 PM
”@SqueezeSharkie is operating on a different tier, comfortably ahead of most traders here. If you’re serious about improving, you should already be following him. It’s free, takes seconds, and the value speaks for itself. $AISP $QNRX $LACG $WLK *3
0 · Reply
stockmoe12
stockmoe12 Feb. 24 at 6:20 PM
$QNRX $PVLA early stage ….
0 · Reply